Benzinga · Sep 11, 2026
GSK Says Plans To Stop Manufacturing At Co's Dresden, Germany Flu Vaccine Manufacturing Site In Summer 2027
- Reuters
NYSE · GSK
GSK plc
Healthcare · Drug Manufacturers - General
$50.01
Down-$0.04 (-0.08%)
Updated Sep 16, 2026, 10:47 AM
SID Score
6.5/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 99.39B
- P/E ratio
- 13.41
- Dividend yield
- 3.35%
- 52-week range
- $39.29 – $61.70
- Volume
- 2.74M
- Avg. volume
- 5.18M
Price performance
GSK price history
1M range · 20 trading sessions · Daily adjusted prices
GSK closed at $50.01 after 20 trading sessions, down 2.23% for the selected period.
- Last close
- $50.01
- Period change
- -2.23%
- Period low
- $48.12
- Period high
- $52.88
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $49.69 | $50.155 | $49.63 | $50.01 | 2.74M |
| Sep 14, 2026 | $50.29 | $50.30 | $49.61 | $50.05 | 3M |
| Sep 11, 2026 | $48.70 | $48.80 | $47.85 | $48.13 | 2.28M |
| Sep 10, 2026 | $48.47 | $48.59 | $47.975 | $48.12 | 2.15M |
| Sep 9, 2026 | $48.815 | $49.16 | $48.60 | $48.63 | 2.41M |
| Sep 8, 2026 | $49.00 | $49.2349 | $48.54 | $48.54 | 3.06M |
| Sep 4, 2026 | $49.70 | $50.06 | $49.66 | $49.89 | 2.29M |
| Sep 3, 2026 | $51.50 | $51.52 | $50.19 | $50.87 | 2.44M |
| Sep 2, 2026 | $50.36 | $51.08 | $50.04 | $50.44 | 2.94M |
| Sep 1, 2026 | $51.11 | $51.26 | $50.465 | $50.66 | 3.27M |
| Aug 31, 2026 | $50.62 | $50.82 | $50.25 | $50.25 | 2.39M |
| Aug 28, 2026 | $50.22 | $50.88 | $49.95 | $50.82 | 3.43M |
| Aug 27, 2026 | $50.945 | $51.03 | $50.165 | $50.27 | 2.47M |
| Aug 26, 2026 | $51.90 | $52.09 | $51.40 | $51.43 | 1.72M |
| Aug 25, 2026 | $51.57 | $52.21 | $51.51 | $52.07 | 2.7M |
| Aug 24, 2026 | $51.54 | $51.9491 | $51.40 | $51.78 | 2.89M |
| Aug 21, 2026 | $51.35 | $52.57 | $51.35 | $52.41 | 2.4M |
| Aug 20, 2026 | $52.57 | $52.63 | $51.86 | $51.96 | 3.6M |
| Aug 19, 2026 | $51.40 | $52.945 | $51.35 | $52.88 | 3.9M |
| Aug 18, 2026 | $50.76 | $51.3531 | $50.65 | $51.15 | 2.83M |
Latest GSK news
The latest Smart Investors Daily articles mentioning GSK.
Stock researchCompany · Overview
GSK research
Overview
Company profile and research snapshot.
Company profile
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Hold
- Average target
- $53.00
- Implied upside
- —
- Analysts
- 7
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 8, 2026 | Deutsche | Hold | — |
| May 28, 2026 | Jefferies | Buy | — |
| May 27, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Deutsche | Hold | — |
| May 6, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 11, 2026
GSK’s mRNA Flu Vaccine Shows Promise, But Can It Deliver Late-Stage?
GSK plc (NYSE:GSK) is advancing its experimental seasonal influenza vaccine into late-stage development after encouraging mid-stage results in both younger and older adults. The mRNA-based candidate generated stronger immune responses than currently approved standard- and high-dose flu vaccines, according to GSK (NYSE:GSK). Its design also targets two important surface proteins on the influenza virus rather […]
SeekingAlpha · Sep 9, 2026
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
Yahoo · Sep 7, 2026
The Shingles Vaccine Is $0 at the Pharmacy. Get the Same Shot at Your Doctor’s Office and the Front Desk Asks for $200 Per Dose.
The shingles vaccine costs nothing under Medicare Part D, yet thousands of beneficiaries walk out of their doctor's office owing hundreds of dollars for the exact same shot. The billing system has a gap, and most patients have no idea it exists until they're already holding the receipt.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
